We can reverse the course of disease.
Generian is working to restore cellular function, amplifying natural signaling networks to reverse the course of disease.
Aging is the predominant risk factor for most diseases.
Over time, cells no longer function as they should – impacting signaling networks that drive cellular stress, leading to chronic disorders. Generian is using insights about the natural process of cellular aging to develop therapies that restore cellular function, amplifying natural signaling networks to reverse the course of disease.
The Approach
Generian’s discovery platform harnesses E3 ligase biology to enhance the activation of beneficial cellular pathways. Our medicines increase specific target protein activity and improve cellular function and healthspan by restoring signaling through the body’s natural biological networks.
The Programs
Leveraging decades of research from some of the foremost experts in age-related diseases and E3 ligase biology, Generian has identified network regulators (TFEB and AMPK) which are validated therapeutic targets essential to cellular function that diminish with age, disease or genetic mutations. Generian’s programs provide an opportunity for clinical proof of mechanism and validation in rare conditions, with expansion into common disorders.
TFEB (or Transcription Factor EB)
plays an essential role in cellular quality control by regulating autophagy and lysosomal biogenesis.
AMPK (or AMP-activated protein kinase)
helps to maintain cellular fitness, playing an essential role in nutrient sensing and appropriate cell metabolism.
Perspectives from our Leadership team
“Our work at Generian is focused on translating research into drugs that can reverse the course of disease in humans. The goal is to help people live better longer.”
Toren Finkel, MD, PhD
CSO
“The Generian discovery platform we have built enables rapid and scalable target discovery through the use of proprietary tools and assays that pinpoint relevant target proteins, identify specific E3 ligases and develop small molecules for further studies.”
Bill Chen, PhD
VP, Drug Discovery
“The therapies we are developing are designed to inhibit specific E3 ligases, thereby preventing the degradation of beneficial target proteins to enhance cellular response and exert a beneficial effect.”
Yuan Liu, PhD
VP, Biology
